A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Stopped early · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer

In brief

The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.

Key facts

Study ID
NCT04165031
Run by
Eli Lilly and Company
People needed
5
Starts
2019-11-28
Expected to finish
2020-10-30
Last updated by the study team
2021-11-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.